These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32944497)

  • 1. A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis.
    Ooi R; Tobino K; Sakabe M; Kawabata T; Hiramatsu Y; Sueyasu T; Yoshimine K
    Respir Med Case Rep; 2020; 31():101197. PubMed ID: 32944497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy.
    Liang I; Chu G; Zielinski R
    Case Rep Oncol; 2023; 16(1):182-187. PubMed ID: 37013108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case report of immune checkpoint inhibitor-related myositis and cholangitis induced by pembrolizumab.
    Yamano T; Hamakawa M; Akaike Y; Ishida T
    Clin Case Rep; 2024 Jul; 12(7):e9153. PubMed ID: 38962456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    Beck TN; Kudinov AE; Dulaimi E; Boumber Y
    BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
    Chai QQ; Du JY; Zhu J; Wu B
    Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
    [No Abstract]   [Full Text] [Related]  

  • 6. Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: Case report and review of published work.
    Koya Y; Shibata M; Shinohara N; Nebuya S; Oe S; Honma Y; Senju M; Sato N; Harada M
    Hepatol Res; 2019 Aug; 49(8):950-956. PubMed ID: 30861263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
    Watanabe H; Kubo T; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2019 Aug; 49(8):762-765. PubMed ID: 31090906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab-related autoimmune hemolytic anemia in a patient with metastatic lung adenocarcinoma: a case report.
    Baek DW; Chae YS
    Yeungnam Univ J Med; 2021 Oct; 38(4):366-370. PubMed ID: 33752275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of simultaneous occurrence of hepatitis and pancreatitis during the combination immunochemotherapy for non-small cell lung carcinoma.
    Tanaka S; Asakawa R; Komuta K; Tanizaki S; Kanai T; Kuroyama M; Shimazu K; Uchida J; Yakushijin T; Ueno K
    Respir Med Case Rep; 2020; 31():101266. PubMed ID: 33134073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
    Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
    Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
    J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
    Kuo CS; Wang CC; Huang YC; Pavlidis S; Liu CY; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
    Thorac Cancer; 2019 May; 10(5):1158-1166. PubMed ID: 30950239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma.
    Spathas N; Economopoulou P; Cheila M; Kotsantis I; Fanouriakis A; Kassara D; Psyrri A
    Front Oncol; 2018; 8():409. PubMed ID: 30319973
    [No Abstract]   [Full Text] [Related]  

  • 17. Undifferentiated carcinoma of the transverse colon with rhabdoid features that developed during treatment of non-small cell lung carcinoma with pembrolizumab: a case report.
    Ashitomi Y; Yano M; Kono M; Suzuki T; Kawamura I; Okazaki S; Kamio Y; Hachiya O; Urano Y; Motoi F
    Surg Case Rep; 2020 Aug; 6(1):196. PubMed ID: 32748092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: A case report.
    Niki M; Nakaya A; Kurata T; Nakahama K; Yoshioka H; Kaneda T; Kibata K; Ogata M; Nomura S
    Mol Clin Oncol; 2019 Feb; 10(2):267-269. PubMed ID: 30680206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma.
    Oki R; Hirakawa Y; Kimura H; Honda K; Hinata M; Abe H; Domoto Y; Tanaka G; Nagase T; Nangaku M
    Intern Med; 2020 Apr; 59(7):977-981. PubMed ID: 31813918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case Report: Fatal Multiorgan Failure and Heterochronous Pneumonitis Following Pembrolizumab Treatment in a Patient With Large-Cell Neuroendocrine Carcinoma of Lung.
    Xie X; Wang F; Qin Y; Lin X; Xie Z; Liu M; Ouyang M; Luo B; Gu Y; Li S; Gu D; Chen R; Zhou C
    Front Pharmacol; 2020; 11():569466. PubMed ID: 33584255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.